Newsroom
Follow us as we passionately pursue our goal of improving life for those with cancer.
Get the latest
-
AVEO Pharmaceuticals acquires rights to novel anti-cancer compound from Mitsubishi Pharma Corporation
Download PDF AVEO’s Human Response Prediction Platform to Guide Clinical Development of Multiple Kinase Inhibitor CAMBRIDGE, MA January 5, 2006 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today that AVEO has acquired from Mitsubishi Pharma Corporation an exclusive license to develop and commercialize Mitsubishi’s novel
Follow us on social media
Media inquiries
For media inquiries, please contact:
John F. Kouten, CEO
JFK Communications, Inc.
jfkouten@jfkhealth.com
Direct: 609-241-7352
Download our media kit:
Meet our leadership team
The AVEO oncology management team comprises executives with years of oncology and pharmaceutical industry experience and expertise with a proven track record for success in bringing important new therapies to patients.